George Bakris to Sympathectomy
This is a "connection" page, showing publications George Bakris has written about Sympathectomy.
Connection Strength
9.314
-
Renal denervation: one step backwards, three steps forward. Nat Rev Nephrol. 2018 10; 14(10):602-604.
Score: 0.644
-
Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
Score: 0.598
-
Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 01 07; 38(2):93-100.
Score: 0.571
-
Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107.
Score: 0.564
-
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
Score: 0.506
-
Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60.
Score: 0.503
-
Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9.
Score: 0.502
-
Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8.
Score: 0.495
-
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27.
Score: 0.492
-
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8.
Score: 0.476
-
The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2014 Jan; 12(1):69-76.
Score: 0.463
-
Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014; 34(5):550-9.
Score: 0.463
-
Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5.
Score: 0.461
-
Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6.
Score: 0.445
-
Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep. 2012 Oct; 14(5):455-61.
Score: 0.425
-
The promise of renal denervation. Cleve Clin J Med. 2012 Jul; 79(7):498-500.
Score: 0.418
-
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
Score: 0.413
-
Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply. Lancet. 2023 04 22; 401(10385):1337-1338.
Score: 0.221
-
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
Score: 0.148
-
Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015 Oct 01; 309(7):F583-94.
Score: 0.129
-
Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015 Apr; 21:20-4.
Score: 0.124
-
Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1.
Score: 0.117
-
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
Score: 0.053
-
Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426.
Score: 0.049
-
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
Score: 0.032